Overview

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Status:
Active, not recruiting

Trial end date:
2021-11-08

Target enrollment:

Participant gender:

Summary

This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Calithera Biosciences, Inc
Incyte Corporation

Treatments:

Nivolumab
Pembrolizumab